As microRNA Field Heats Up, Biotech Begins to Embrace the Technology. Will Pharma Follow? | GenomeWeb

For years, the importance of microRNAs has been almost entirely appreciated by academic researchers. But in recent months, as evidence accumulates linking these small non-coding RNAs to both normal biological functioning and disease accumulates, the biotech industry — known for pioneering new technologies — has started to take notice.

But what of big pharma? In light of that industry's slow acceptance of RNAi as a therapeutic modality even with promising clinical data available, it is likely to be some time before it truly embraces miRNAs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.